Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study evaluated the long-term safety of ritlecitinib in adolescents with alopecia areata and found it to be well-tolerated without new safety concerns over approximately five years, with common adverse events including positive SARS-CoV-2 tests, acne, headache, and nasopharyngitis.

In this study, ritlecitinib, an oral JAK3/TEC inhibitor, was evaluated for safety in patients aged 12 and older with alopecia areata across four clinical trials up to 36 months, showing a safety profile with reported adverse events and lab abnormalities summarized per dosing groups.

This study suggests that oral budesonide may not effectively maintain remission in Crohn's disease beyond three months, with minor benefits that are outweighed by increased rates of treatment-related adverse events.

This study reports no new findings but provides corrected figures for the long-term safety and efficacy of ritlecitinib in treating alopecia areata from the ALLEGRO-LT phase 3 study.

This report details a case of hair, nail, and pigmentary disorders occurring 10 months after starting abemaciclib for metastatic breast cancer, highlighting that cutaneous side effects, although less frequent, can lead to discontinuation in 25% of cases.

This study found that Baricitinib significantly reduced hair loss and immune response in a mouse model of alopecia areata.

This study identified mefloquine as a potent inducer of lethal ER stress that effectively eliminated vemurafenib-resistant and sensitive melanoma cells, suggesting its potential for repurposing as a melanoma treatment.

This study found that more than half of patients with severe alopecia areata who reduced their baricitinib dose from 4mg to 2mg maintained a clinical response for up to 2 years.

This study found that Janus kinase inhibitors were effective in inducing clinical and biochemical remission in patients with Ulcerative Colitis while exhibiting an expected safety profile, though 30% discontinued treatment due to adverse events or lack of efficacy.

This article reviews historical and traditional uses of the herb Bacopa monnieri, or Brahmi, for enhancing memory and other medicinal benefits, but presents no new research findings.

RY-023, a specific drug, can improve early stage memory learning without affecting general activity in rats, but it's less effective for later learning stages and doesn't impact memory recall.

This study reviewed the safety of JAK inhibitors for alopecia areata, finding that common side effects included headache and acne, with varying risks for respiratory infections and no increased risk of serious adverse events.

This narrative review found that ritlecitinib shows consistent effectiveness and a favorable safety profile for treating alopecia areata in clinical trials and real-world settings, with progressive hair regrowth observed, particularly when treatment is initiated early and maintained appropriately.

In this open-label study of post-menopausal women with frontal fibrosing alopecia, researchers found that 12 weeks of baricitinib monotherapy significantly reduced disease activity as measured by the Lichen Planopilaris Activity Index, improved patient-reported scalp hair growth, but showed no significant change in eyebrow growth.

This study suggests that cutaneous adverse reactions to bortezomib and lenalidomide are more frequent than reported, impacting patients' quality of life and may require dermatological consultation for proper management.

This report highlights that oral Janus kinase inhibitors, including baricitinib, ritlecitinib, deuruxolitinib, and brepocitinib, show promise for treating alopecia areata by promoting substantial hair regrowth with mild-to-moderate side effects, positioning them as a favorable alternative to corticosteroids.

This study examined molecular predictors of ritlecitinib efficacy in treating alopecia areata, highlighting the role of JAK3-dependent inflammation and follicular integrity as important factors in understanding disease mechanisms and potential therapeutic effectiveness.

In a single-center study, adolescents with moderate-to-severe alopecia areata treated with ritlecitinib 50 mg daily for 24 weeks showed significant hair regrowth, with 27.3% achieving near-complete regrowth and 45.5% substantial improvement, without serious safety concerns, according to these researchers.

This study found that in Asian patients aged 12 and older with alopecia areata and significant hair loss, ritlecitinib showed clinical efficacy in improving hair regrowth and eyebrow and eyelash scores over 48 weeks, with an acceptable safety profile observed throughout.

In this case report, researchers identified a potential adverse skin reaction, called SDRIFE or Baboon syndrome, caused by the drug tofacitinib in a 19-year-old woman being treated for alopecia subtotalis, leading the authors to recommend discontinuation of the drug.

This review summarizes the composition, bioactive functions, and potential industrial applications of rice bran polysaccharides, focusing on how extraction methods and modifications impact their biological activities.

In this survey of dermatologists, pimozide was most commonly identified as the preferred first-line antipsychotic for treating delusions of parasitosis, followed by risperidone.

ASLAN004 was safe and well-tolerated, supporting further development for treating certain diseases.

This study observed that JAK inhibitors were safe and effective for patients with moderate-to-severe alopecia areata and comorbid latent hepatitis B or stable tuberculosis, with careful monitoring and selective prophylaxis.

This case report observed vemurafenib-induced pityriasis amiantacea, a scalp scaling reaction, in a patient with metastatic melanoma, which was managed symptomatically without altering vemurafenib treatment.

This review article summarized the design, synthesis, and application of innovative delivery systems for berberine, highlighting their potential to enhance wound healing through improved bioactivity and bioavailability, particularly in challenging conditions like diabetic and infected wounds.

In a Belgian cohort study, nearly 90% of alopecia areata patients treated with oral baricitinib experienced hair regrowth, with more than 70% achieving a favorable SALT score, particularly in patchy cases, though some relapsed post-treatment. No serious adverse events were noted.